Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 44Neoplasm Metastasis 5Ovarian Neoplasms 2Neoplasms, Hormone-Dependent 2Carcinoma, Lobular 2Carcinoma, Ductal, Breast 2Advanced Breast Cancer 2Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Medullary cystic kidney disease 1 1Lymphoma, Non-Hodgkin 1Leiomyosarcoma 1Hormone-sensitive Metastatic Breast Cancer 1HER2-positive Breast Cancer 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Breast Neoplasm Malignant Female 1Breast Diseases 1Breast Cancer Metastatic 1

Interventions

pazopanib 2Trabectedin 2Doxorubicin 2sapanisertib 1rucaparib 1pembrolizumab 1itacitinib 1baricitinib 1avelumab 1Vorinostat 1TTI-621 1PTC596 1Letrozole 1Ifosfamide 1INCB039110 1Docetaxel 1Dacarbazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leiomyosarcoma × Letrozole × Clear all
NCT00414076 2018-11-20

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

M.D. Anderson Cancer Center

Phase 2 Terminated
9 enrolled 7 charts
GynecologicSarcoma

Leiomyosarcoma, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡